NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today reported its full year 2025 financial results and provided a fourth quarter business update.
Read more at globenewswire.comOrchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
Provided By GlobeNewswire – Last update: